Selecta Biosciences Inc

-0.06 (-4.62%)
Products, Strategic Combinations, Regulatory

Selecta Biosciences Announces Partnership Advancements And Clinical Trial Updates

Published: 06/13/2022 11:41 GMT
Selecta Biosciences Inc (SELB) - Selecta Biosciences Announces Partnership Advancements and Clinical Trial Updates.
Selecta - Sarepta Extends Research License and Option Agreement for Immtor in Duchenne Muscular Dystrophy and Certain Limb-girdle Muscular Dystrophies.
Selecta Biosciences Inc - Selecta to Receive a $2 Million Payment From Sarepta Extending Their Option Periods Under Agreement to Q1 2023.
Selecta - Enrollment in Dissolve Ii Continues to Advance With Full Enrollment Anticipated by End of Q2 2022.
Selecta Biosciences Inc - Dissolve I & Ii Studies Remain on Track for Completion in Q4 2022 With Joint Topline Data in Q1 2023.